Skip to main content
. 2016 Jan 7;310(6):G347–G358. doi: 10.1152/ajpgi.00326.2015

Fig. 1.

Fig. 1.

Effects of microRNA-155 (miR-155) deficiency on colitis-associated colon cancer. A: RT-PCR assessment of gene expression of miR-155-5p in tumor and normal surrounding tissue of patients with colon cancer. B: impact of azoxymethane (AOM)-dextran sulfate sodium (DSS) treatment on survival of miR-155−/− mice. WT, wild-type mice; WT-A/D, WT mice injected with a single 10 mg/kg dose of AOM; miR-155−/− A/D, miR-155−/− mice injected with a single 10 mg/kg dose of AOM. C and D: polyp count and size after AOM-DSS treatment. NT, no tumor. E: symptom score (body weight loss + blood in stool + diarrhea). F: colonic dysplasia in AOM-DSS-treated mice. ND, no dysplasia; LGD, low-grade dysplasia; D, dysplasia; HGD, high-grade dysplasia. G: representative hematoxylin-eosin-stained sections of colon tissue after AOM-DSS treatment. Values are means ± SE; n = 15 cancer patients, or n = 11–12 mice per group. *P < 0.05 vs. WT. ∧P < 0.05 vs. WT-A/D.